LBA23 Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study
Year: 2025
Type: conference-abstract
Source: Annals of Oncology
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shandong Tumor Hospital, Shandong First Medical University, Sichuan Cancer Hospital, Sun Yat-sen University Cancer Center, Zhongnan Hospital of Wuhan University, Tianjin Medical University Cancer Institute and Hospital, Jiangxi Provincial Cancer Hospital, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Zhejiang Cancer Hospital, Jiangsu Province Hospital, Nanjing Medical University, Hunan Cancer Hospital, Fujian Provincial Cancer Hospital, Weifang People's Hospital, First Hospital of Jilin University, Hubei Cancer Hospital, Kelun Group (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Harbin Medical University, European Society of Cardiology, Chinese Academy of Sciences, Chongqing University, Sun Yat-sen University, Anhui Medical University, Government of Jiangsu Province, Dalian University of Technology, Fudan University, Ningxia Medical University, Zhengzhou University, Xinjiang Medical University, European Society for Medical Oncology, Nanjing Medical University, China Medical University, Hebei University, Tianjin Medical University, University of Chinese Academy of Sciences, Dalian Medical University, Shandong First Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen University Cancer Center, Daiichi Sankyo Europe
OpenAlex ID: W4416391850